Aminocaproic acid (AMICAR)

Generic Name: Aminocaproic acid

AMICAR (aminocaproic acid) is 6-aminohexanoic acid, which acts as an inhibitor of fibrinolysis.

Its chemical structure is:

 AMICAR® (aminocaproic acid)  Structural Formula Illustration

AMICAR (aminocaproic acid) is soluble in water, acid, and alkaline solutions; it is sparingly soluble in methanol and practically insoluble in chloroform.

AMICAR (aminocaproic acid) Oral Solution for oral administration, contains 0.25 g/mL of aminocaproic acid with methylparaben 0.20%, propylparaben 0.05%, edetate disodium 0.30% as preservatives and the following inactive ingredients: sodium saccharin, sorbitol solution, citric acid anhydrous, natural and artificial raspberry flavor and an artificial bitterness modifier.

Each AMICAR (aminocaproic acid) Tablet, for oral administration contains 500 mg or 1000 mg of aminocaproic acid and the following inactive ingredients: povidone, crospovidone, stearic acid, and magnesium stearate.

No health feed found.

Aminocaproic acid binds reversibly to the kringle domain of plasminogen and blocks the binding of plasminogen to fibrin and its activation to plasmin. With NO activation of plasmin, there is a reduction in fibrinolysis. This consequently will reduce the amount of bleeding post surgery. Elevated plasma levels of lipoprotein(a) have been shown to increase the risk of vascular disease. Lipoprotein 9a)a has two components, apolipoprotein B-100, linked to apolipoprotein (a). Aminocaproic acid may change the conformation of apoliprotein (a), changing its binding properties and potentially preventing the formation of lipoprotein (a).

Aminocaproic acid (Amicar) is FDA-approved for use in the treatment of acute bleeding due to elevated fibrinolytic activity. It also carries an Orphan Drug designation from the FDA for the prevention of recurrent hemorrhage in patients with traumatic hyphema. In clinical practice, aminocaproic acid is frequently used off-label for control of bleeding in patients with severe thrombocytopenia, control of oral bleeding in patients with congenital and acquired coagulation disorders, control of perioperative bleeding associated with cardiac surgery, prevention of excessive bleeding in patients on anticoagulation therapy undergoing invasive dental procedures, and reduction of the risk of catastrophic hemorrhage in patients with acute promyelocytic leukemia.

AMICAR (aminocaproic acid) is generally well tolerated. The following adverse experiences have been reported:


Edema, headache, malaise.

Hypersensitivity Reactions

Allergic and anaphylactoid reactions, anaphylaxis.


Bradycardia, hypotension, peripheral ischemia, thrombosis.


Abdominal pain, diarrhea, nausea, vomiting.


Agranulocytosis, coragulation disorder, leukopenia, thrombocytopenia.


CPK increased, muscle weakness, myalgia, myopathy, myositis, rhabdomyolysis.


Confusion, convulsions, delirium, dizziness, hallucinations, intracranial hypertension, stroke, syncope.


Dyspnea, nasal congestion, pulmonary embolism.


Pruritis, rash.

Special Senses

Tinnitus, vision decreased, watery eyes.


BUN increased, renal failure. There have been some reports of dry ejaculation during the period of AMICAR (aminocaproic acid) treatment. These have been reported to date only in hemophilia patients who received the drug after undergoing dental surgical procedures. However, this symptom resolved in all patients within 24 to 48 hours of completion of therapy.

An identical dosage regimen may be followed by administering AMICAR (aminocaproic acid) Tablets or AMICAR (aminocaproic acid) Oral Solution as follows:

For the treatment of acute bleeding syndromes due to elevated fibrinolytic activity, it is suggested that 5 AMICAR (aminocaproic acid) 1000 mg Tablets or 10 AMICAR (aminocaproic acid) 500 mg Tablets (5 g) or 20 milliliter of AMICAR (aminocaproic acid) Oral Solution (5 g) be administered during the first hour of treatment, followed by a continuing rate of 1 AMICAR (aminocaproic acid) 1000 mg Tablet or 2 AMICAR (aminocaproic acid) 500 mg Tablets (1 g) or 5 milliliter of AMICAR (aminocaproic acid) Oral Solution (1.25 g) per hour. This method of treatment would ordinarily be continued for about 8 hours or until the bleeding situation has been controlled.

Prolongation of the template bleeding time has been reported during continuous intravenous infusion of AMICAR (aminocaproic acid) at dosages exceeding 24 g/day. Platelet function studies in these patients have not demonstrated any significant platelet dysfunction. However, in vitro studies have shown that at high concentrations (7.4 mMol/L or 0.97 mg/mL and greater) aminocaproic acid inhibits ADP and collagen-induced platelet aggregation, the release of ATP and serotonin, and the binding of fibrinogen to the platelets in a concentration-response manner. Following a 10 g bolus of AMICAR (aminocaproic acid) , transient peak plasma concentrations of 4.6 mMol/L or 0.60 mg/mL have been obtained. The concentration of AMICAR (aminocaproic acid) necessary to maintain inhibition of fibrinolysis is 0.99 mMol/L or 0.13 mg/mL. Administration of a 5 g bolus followed by 1 to 1.25 g/hr should achieve and sustain plasma levels of 0.13 mg/mL. Thus, concentrations which have been obtained in vivo clinically in patients with normal renal function are considerably lower than the in vitro concentrations found to induce abnormalities in platelet function tests. However, higher plasma concentrations of AMICAR (aminocaproic acid) may occur in patients with severe renal failure.

You should not flush aminocaproic acid down the toilet or pour them into a drain unless instructed to do so. It is important to properly discard this product when it is expired or no longer needed. Consult your pharmacist for more details about how to safely discard your product.

Before using this drug, tell your doctor if:

  • You are pregnant or breastfeeding. This is because, while you are expecting or feeding a baby, you should only take medicines on the recommendation of a doctor.
  • You are taking any other medicines. This includes any medicines you are taking which are available to buy without a prescription, such as herbal and complementary medicines.
  • You have allergy with any of active or inactive ingredients of aminocaproic acid or other medications.
  • You have any other illnesses, disorders, or medical conditions.
  • You have blood clots.
  • You are taking any of these drugs: Factor IX complex or anti-inhibitor coagulant complex.

Tell all of your health care providers that you take this medicine. This includes your doctors, nurses, pharmacists, and dentists.

Have blood work checked as you have been told by the doctor. Talk with the doctor.

This medicine may affect certain lab tests. Tell all of your health care providers and lab workers that you take this medicine (aminocaproic acid tablets).

Is it safe during pregnancy or breastfeeding?

There are no adequate studies in women for determining risk when using aminocaproic acid during pregnancy or while breastfeeding. Please always consult with your doctor to weigh the potential benefits and risks before taking aminocaproic acid. Aminocaproic acid is pregnancy risk category C, according to the US Food and Drug Administration (FDA).

FDA pregnancy risk category reference below:

  • A=No risk
  • B=No risk in some studies
  • C=There may be some risk
  • D=Positive evidence of risk
  • X=Contraindicated
  • N=Unknown

Share Your Opinion

Please fill the details

Did you find this helpful?

Your feedback will help us improve the product

Disclaimer :

The texts and materials and any other information published on this site serve a purely informative purpose, and have no official or legal status in the form they are published here. We do not guarantee any authenticity to the information provided here, kindly confirm the exactness of the content published here from relevant sources before you act on any information provided on this site.

Check your area pincode

Sorry, right now we are not available in your area

Send Your Message


By signing up, I agree to terms